Genetic association between a single nucleotide polymorphism in Interleukin-16 (rs4072111) and susceptibility to chronic HCV infection in an Iranian population

Maryam Karkhane1, Seyed Reza Mohebbi2, Pedram Azimzadeh1, Hasti Avarandeh3, Shabnam Kazemian2, Afsaneh Sharifian2, Behzad Hatami2, Hamid Asadzadeh Aghdai2
1Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Foodborne and waterborne diseases research center, Research institute for gastroenterology and liver diseases, Shahid Beheshti University of Medical Sciences

ABSTRACT

Aim: Our goal was to identify the putative association of rs4072111 variant in IL-16 gene and HCV susceptibility in an Iranian population.

Background: Interleukin 16 (IL-16), a multifunctional cytokine, plays a vital role in modulation of immune system.

Methods: In present case control and cross sectional study, IL-16 gene variant in 300 patients with hepatitis C (HCV) infection and 300 healthy individuals were analyzed. To evaluate this possible association, genomic DNA from venous blood was extracted and genotypes of IL-16 rs4072111 variant were determined by polymerase chain reaction- Fragments Length Polymorphism Technique (PCR-RFLP). Then, rs4072111 C/T genotypes frequency and allelic distribution were evaluated in each group.

Results: The results of genotyping showed 82% CC, 17.3% CT, 0.7% TT in the control group and 78% CC, 20% CT and 2% TT in the case group. The distribution of rs4072111 C allele was 90.7% in controls and 88% in case group respectively. However, no correlation between IL-16 rs4072111 C/T variants and susceptibility to chronic HCV infection was found in the present study.

Conclusion: We concluded the rs4072111 C/T cannot be considered as a proper biomarker to identify susceptibility to chronic hepatitis C virus infection.

Keywords: profile.

Introduction

Despite the advent of direct acting antiviral (DAA) agents, Hepatitis C virus (HCV) infection is still a matter of concern around the world. HCV is an important reason of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma(1). Approximately, 50 % of patients have successful response to previous standard remedy with pegylated interferon (peg-IFN) plus Ribavirin (2, 3). In spite of intensive efforts in HCV antiviral therapy, definite treatment is not achieved which may due to lack of understanding of the viral contamination process and immune response defects in interaction with HCV (4). On the other hand, no effective vaccine has been designed, produced and applied to prevent HCV infection, yet. Emerging observations suggest that both immunologic and virologic events in different stages of infection determine the disease outcome. Spontaneous clearance
of HCV observed in 15-45% of acute HCV patients and is associated with a widely specific and powerful cellular immune response. In addition, threshold frequency of CTL is essential for HCV clearance (5, 6). Immunity against HCV is connecting with vigorous CD4+ T cells and IL-16 plays a crucial role in T cell polarization and T cell response regulation and also, it governs trafficking and biological properties of TCD4+. Interleukin 16 (IL-16) is a potent anti-inflammatory cytokine that is secreted by a variety of cell types such as lymphocyte and epithelial cells. This CD4 co-receptor specific ligand is a multi-functional mediator that initially determined as a lymphocyte chemo-attractant cells (LCF). It can also attract activated T CD4+ cells and re-circulate and activate antigen presenting cells such as monocytes, macrophage and dendritic cells. Although, IL-16 can stimulate the expression of different pro-inflammatory cytokines such as IL-1β, IL-4, TNF-α, IL-12 and IL-15 (7, 8). In addition, it works in concert with IL-12 and IL-15 to promote CD4+ T cell proliferation and also IL-2α induction on CD4 T cell (9, 10). Most studies emphasize anti-inflammatory property of IL-16 (11, 12). IL-16 gene was located on chr15.q26.3 and genetic polymorphisms in DNA sequence of IL-16 gene may cause to cytokine production and/or activity. Therefore, IL-16 polymorphisms were investigated in several diseases and its association with autoimmune diseases; viral hepatitis B, HBV related HCC and a range of cancers, including prostate, gastric and colorectal cancer has been evaluated (7, 10, 13-16). The possible association between SNPs of IL-16 gene and susceptibility to chronic HCV, has not been investigated in Iranian population, therefore we decided to perform this study for the first time to assess the role of rs4072111 T/C polymorphism HCV chronic infection in a group of Iranian HCV patients in comparison with healthy controls.

Methods

Study population

In this case-control study, 300 patients with chronic HCV were collected as case group and 300 healthy individuals were studied as control group. Gastroenterology and Liver Diseases Research institute, Shahid Beheshti University of Medical Sciences provided the funding and supported HCV patients and healthy controls sample collection process. Healthy individuals with negative results for anti HCV antibody by ELISA and also without a history of liver associated diseases were included in the study. Selection criteria for patients group defined as negative results for HBs antigen, HBc antibody (Ab) and positive for anti-HCV Ab via enzyme linked immunosorbent assay (ELISA) tests (Diaprost Diagnostics, Italy). Patients with Hepatitis B virus co-infection were excluded from the study.

DNA extraction

Genomic DNA was extracted from peripheral blood cells of patients and healthy control subjects by using standard phenol-chloroform extraction method (17). The appropriate quality and standard quantity of the extracted DNA were then checked by Nanodrop Spectrophotometer (Thermo Fisher Scientific Inc; Waltham, MA).

IL-16 genotyping

In order to determine genotypes of IL-16 rs4072111, Restriction fragments length polymorphism (PCR-RFLP) method was utilized following the polymerase chain reaction (PCR) amplification.

The PCR conditions for amplification of target sequence were as follows: 95°C for 5 min; 35 cycles of 95°C for 30 s, 58.4°C for 30 s, and 72°C for 30 s; 72°C for 10 min as last extension. The sequence of primers included forward primer: 5'- CACTGTATCCCCGTCCAGTC-3' and reverse primer: 5'- TCCAGGTACAAACCCAGCCAG C -3' (18) that amplified PCR product about 164bp.

The final volume of PCR reaction was 25 µl which comprised of 100 ng of template, 200 µM dNTPs (Fermentas, Latvia), 10 pmol of forward and reverse primers, 1.25 U of Taq polymerase.

The enzymatic digestion process for differentiation of rs4072111 genotypes was performed by BsmAI restriction enzyme (Thermoscientific, USA) at 37°C overnight.

The final products of digestions were run on 2.5% w/v agarose (Hoffmann la Roche AG, Basel, Switzerland) gel, which were stained with green viewer to visualize the fragments patterns by using UV documentation instrument (Vilber Lourmat, France).
Statistical analysis

The demographic data of chronic HCV patients and healthy subjects were shown as frequency (percentage) and mean ± standard error of mean. T-test and Chi-square tests were used to evaluate the data. The adjusted logistic regression analysis was used to survey the possible association between rs4072111 C/T variants or allelic frequencies and susceptibility to chronic HCV infection. To assess this survey odd ratio (OR) and confidence interval 95% (95% CI) illustrated the results. Statistical analysis was two sided, and p<0.05 was considered significant.

Results

A total of 600 subjects were included in this study, containing 300 healthy controls and 300 chronic HCV patients. Control group contained 152 (50.7%) males and 148 (49.3%) females and case group comprised of 236 (78.7%) male and 64 female (21.3%) subjects. Along with the random sampling, we tried to select both genders equally in control group, in versus of the case group, which male gender was dominant.

The mean age of control and case groups was 45.13 ± 0.95 and 44.88 ±0.82 years respectively. Although the mean age of control group was slightly higher than case group, the difference was not significant (p=0.84).

We studied the distribution of rs4072111 C/T variants in healthy subjects and chronic HCV patients in an Iranian population that the details were illustrated in table 1. The rs4072111 CC was the most frequent variant in both healthy control and patient groups. However, no meaningful difference was observed in the distribution rs4072111 C/T variants in case and control groups.

Table 1. The distribution pattern of rs4072111 C/T variants and associated allelic frequency

| SNP Variants | Control Group (n=300) | Case Group (n=300) | Adjusted a OR (95% CI), P value |
|--------------|-----------------------|--------------------|--------------------------------|
| CC           | 246 (82%)             | 234 (78%)          | 1.00, Reference group          |
| CT           | 52 (17.3%)            | 60 (20%)           | 1.18 (0.771-1.825); 0.437      |
| TT           | 2 (0.7%)              | 6 (2%)             | 2.98 (0.563-15.844); 0.199     |
| Alleles      |                       |                    |                                |
| C            | 544 (90.7%)           | 528 (88%)          | 1.00, Reference group          |
| T            | 56 (9.3%)             | 72 (12%)           | 1.33 (0.918-1.934); 0.132      |

Table 2. Separation of rs4072111 C/T variants and related allelic distribution by gender

| Male gender | Female gender |
|-------------|---------------|
| SNP Frequency | Control group | Case group | Control group | Case group |
| CC          | 127 (83.6%)   | 180 (76.3%) | 119 (80.4%)   | 54 (84.4%)  |
| CT          | 24 (15.8%)    | 51 (21.6%)  | 28 (18.9%)    | 9 (14.1%)   |
| TT          | 1 (0.7%)      | 5 (2.1%)    | 1 (0.7%)      | 1 (1.6%)    |
| Allelic Frequency | 340 (87.6%)   | 330 (85.1%) | 204 (96.2%)   | 198 (93.4%) |
| T           | 48 (12.4%)    | 58 (14.9%)  | 8 (3.8%)      | 14 (6.6%)   |

Figure 1. RFLP pattern of IL16 rs4072111 C/T. rs4072111 C and T showed 164 bp and 140 bp along with 24 bp respectively. 50 bp DNA ladder (Thermo Fisher Scientific, USA) was used to distinguish the fragments on the electrophoresis gel.
The ancestral allele for position of rs4072111 C/T is C allele. Data analysis of allelic count showed in consistent of high frequency of rs4072111 CC variant, C allele was more frequent rather than T allele in Iranian population.

We also studied the rs4072111 C/T polymorphisms and allelic frequencies in different genders. We observed no significant difference between control and case groups regarding genders. The results were illustrated in table 2. In addition, restriction pattern of PCR product with 164 bp size was depicted in figure 1.

Discussion

IL-16 is an immunomodulator cytokine which mainly produced by T CD8+. However, macrophage and B cells secrete IL-16 against viral and bacterial infections. IL-16 plays as chemo-attractant role for certain immune cells expressing the CD4 and assumed as a natural ligand for CD4 molecule which leads to initiation of intracellular pathway through activation of stress-activated protein kinase (SAPK) signaling in T helper CD4+ (19). Lympho-attractant property of IL-16 causes to immune cell recruitment and then, directs the immune response (20). Strong specific T helper CD4+ connected with successful HCV clearance. Therefore, IL-16 with TCD4+ adherence and guidance assume as a major component in immunity against HCV and achievement of spontaneous HCV resolution (21). Moreover, after binding to CD4 molecules, IL-16 triggers the secretion of inflammatory cytokines including TNF-α, IL-1β and IL-4 (22).

Several researches studied the multifunctional properties of IL-16 in variety range of diseases. In a cell culture based study, Corinne Amiel and colleagues proved a significant inhibitory activity of recombinant IL-16 on viral transcription and replication in human immunodeficiency virus infection (23).

Multiple studies showed anti-inflammatory activity of IL-16 cytokine. Klimiuk PA et al. suggest supplemental therapy of rheumatoid arthritis patients with IL-16 as a novel anti-inflammatory treatment (11). In consistent with anti-inflammatory property, Caterina Musolino and colleagues studied the IL-16 concentration in multiple myeloma before treatment and showed high levels of this cytokine in tumor locations (12).

The patient’s susceptibility associated interaction between immune system and HCV particles well not realized. In addition, several studies have been recently reported association of the most common variants in host genome and susceptibility to viral infections (24-27). The evidences revealed that genetic contents of innate and adaptive immune response may have effect on the natural history of HCV infection (28, 29). Genetic polymorphisms of IL-16 may change the folding of cytokine, biological function and can determine the bio-availability of cytokine. This change in cytokine concentration may cause to alteration of cytokine environment and leads to different outcome of disease (30).

Several researches showed the role of IL-16 gene polymorphism with auto-immune diseases (31-35). Xue-jiang Gu et al. revealed the correlation between Grave’s disease susceptibility and IL-16 gene’s variation (32). In another similar study, variation of IL-16 gene recognized as biomarker for facility of Grave’s autoimmune disease diagnosis (36). Also, -295 T>C polymorphisms in promoter region of IL-16 is associated with increased IL-16 expression which was studied in Crohn’s disease (31). Lew BL et al. emphasized the involvement of IL-16 polymorphisms in autoimmune diseases promotion. So that, they showed the rs17875491 and rs11073001 participation in Alopecia areata autoimmune non-scarring hair loss emerging (37).

In the other hand, many issues addressed the major role of IL-16 polymorphism in risk of various kinds of cancers (38-40). Rs4072111 C/T polymorphism was assumed such as risk marker for nasopharyngeal carcinoma occurrence (40). Hughes L et al. illustrated the prostate cancer diagnosis and screening strategy via genetic polymorphisms of IL-16 which are related to micro-RNA binding site products. In this assay, rs1131445 TT genotype presumed risk factor for earlier time appearance of prostate cancer among African-American ethnicity (41).

Rs4072111 was considered as suitable susceptibility biomarker for progression of chronic HBV infection by Romani et al. They suggest that, rs4072111 T allele increased in chronic HBV patients compared to healthy individuals (42).

In addition, Eed Em et al. found that rs4072111 CT can consider as HBV biomarker and rs4072111 TT
polymorphism increase the risk of HBV-associated HCC in Saudi population.(43). These results are consistent with Shan Li et al. who showed that significant increase of IL-16 rs4072111 TT in Chinese population with HCC (10).

To our knowledge, no study was investigated the potent role of IL-16 variants in chronic HCV patients’ susceptibility, up to now. In this research, we evaluated the distribution of rs4072111 C/T in patients with chronic HCV patients in comparison with healthy control group. The results of our research showed no significant difference between distribution of rs4072111 C/T polymorphisms and allelic frequency in chronic HCV patients in comparison to healthy people. It seems that rs4072111 C/T polymorphism cannot be considered as a susceptibility biomarker of chronic HCV infection and other IL-16 single nucleotide polymorphisms should be analyzed in a larger study group to elucidate the role of this cytokine in chronicity of HCV infection.

**Acknowledgment**

The authors would like to appreciate the endeavor of the Gastroenterology and Liver Diseases Research institute staff to collect blood specimens.

**Conflict of interests**

The authors declare that they have no conflict of interest.

**References**

1. Karkhane M, Mohebbi SR, Azimzadeh P, Niasr MS, Sarbazi MR, Sharifian A, et al. Lack of association between interleukin 28B gene polymorphisms (rs8099917G/T, rs12979860 C/T) and susceptibility to chronic hepatitis C virus infection, Tehran, Iran. Gastroenterol Hepatol Bed Bench 2016;9:S29.

2. Radkowski M, Opoka-Kegler J, Cortes KC, Bukowska-Osko I, Perlejewski K, Pawelczyk A, et al. Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin. J Gen Virol 2014;95:2004-9.

3. Liu Z, Zhang X, Yu Q, He JJ. Exosome-associated hepatitis C virus in cell cultures and patient plasma. Biochem Biophys Res Commun 2014;455:218-22.

4. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009;119:1745.

5. Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, Lewinsohn DM, et al. Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med 2005;201:1725-31.

6. Cox AL, Mosbruger T, Mao Q, Liu Z, Wang XH, Yang HC, et al. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 2005;201:1741-52.

7. Xu LL, Song ZC, Shang K, Zhao LQ, Zhu ZS. Non-association of IL-16 rs4778889 T/C polymorphism with cancer risk in Asians: a meta-analysis. Asian Pac J Cancer Prev 2014;15:803-5.

8. Skundric DS, Cukicshank WW, Drulovic J. Role of IL-16 in CD4+ T cell-mediated regulation of relapsing multiple sclerosis. J Neuroinflammation 2015;12:78.

9. Mathy N, Scheuer W, Lanzendörfer M, Honold K, Ambrosius D, Norley S, et al. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology 2000;100:63-9.

10. Li S, Deng Y, Chen ZP, Huang S, Liao XC, Lin LW, et al. Genetic polymorphism of interleukin-16 influences susceptibility to HBV-related hepatocellular carcinoma in a Chinese population. Infect Genet Evol 2011;11:2083-8.

11. Klimiuk PA, Goronzy JJ, Weyand CM. IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J Immunol 1999;162:4293-9.

12. Musolino C, Allegra A, Innao V, Allegra AG, Pioggia G, Gangemi S. Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma. Mediators Inflamm 2017;2017:1852517.

13. Behelgardi A, Hosseini SM, Mohebbi SR, Azimzadeh P, Derakhshani S, Karimi K, et al. A Study on Genetic Association of Interleukin-16 Single Nucleotide Polymorphism (rs1131445) With Chronic Hepatitis B Virus Infection in Iranian Patients. JJM 2015;8:e23411.

14. Akahane M, Watanabe M, Inoue N, Miyahara Y, Arakawa Y, Inoue Y, et al. Association of the polymorphisms of chemokine genes (IL8, RANTES, MIG, IP10, MCP1 and IL16) with the pathogenesis of autoimmune thyroid diseases. Autoimmunity 2016;49:312-9.

15. Kashfi SM, Farahbaksh FB, Mojarad EN, Mashayekhi K, Azimzadeh P, Romani S, et al. Interleukin-16 polymorphisms as new promising biomarkers for risk of gastric cancer. Tumor Biol 2016;37:2119-26.

16. Zhao YH, Tao L, Wang B, Nie P, Tang YM, Zhu M. Interleukin-16 Gene Polymorphisms rs4778889, rs4072111, rs11556218, and Cancer Risk in Asian Populations: A Meta-Analysis. Genet Test Mol Biomarkers 2014;18:174-82.

17. Sambrook J, Fritsch E, Maniatis T. Molecular Cloning: A Laboratory Manual. Ford N, Nolan C, Ferguson M, eds. Cold Spring Harbor Laboratory Press. 4th edition. Cold Spring Harbor, New York 2012:47-53.

18. Gao LB, Rao L, Wang YY, Liang WB, Li C, Xue H, et al. The association of interleukin-16 polymorphisms with IL-16
serum levels and risk of colorectal and gastric cancer. Carcinogenesis 2009;30:295-9.

19. Krautwald S. IL-16 activates the SAPK signaling pathway in CD4+ macrophages. J Immunol 1998;160:5874-9.

20. Wilkinson J, Radkowski M, Eschbacher JM, Laskus T. Activation of brain macrophages/microglia cells in hepatitis C infection. Gut 2010;59:1394-400.

21. Day CL, Lauer GM, Robbins GK, McGovern B, Wurcel AG, Gandhi RT, et al. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol 2002;76:12584-95.

22. Liu C, Mills J, Dixon K, Vennarini J, Cunningham M, Del Vecchio A, et al. IL-16 signaling specifically induces STAT6 activation through CD4. Cytokine 2007;38:145-50.

23. Amiel C, Darcissac E, Truong MJ, Dewulf J, Loyens M, Mouton Y, et al. Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression. J Infect Dis 1999;179:83-91.

24. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-45.

25. Ben-Ari Z, Mor E, Papo O, Kfir B, Sulkes J, Tambur AR, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol 2003;98:144-50.

26. Cheng PL, Eng HL, Chou MH, You HL, Lin TM. Genetic polymorphisms of viral infection-associated Toll-like receptors in Chinese population. Transl Res 2007;150:311-8.

27. Knapp S, Yee L, Frodsham A, Hennig B, Hellier S, Zhang L, et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun 2003;4:411-9.

28. Bengsch B, Thimme R, Blum HE. Role of Host Genetic Factors in the Outcome of Hepatitis C Virus Infection. Viruses-Basel 2009;1:104-25.

29. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.

30. Smith AJ, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 2009;20:43-59.

31. Glas J, Török H, Unterhuber H, Radlmayr M, Folwaczny C. The−295T-to-C promoter polymorphism of the IL-16 gene is associated with crohn’s disease. J Clin Immunol 2003;106:197-200.

32. Gu XJ, Cui B, Zhao ZF, Chen HY, Li XY, Wang S, et al. Association of the interleukin (IL)-16 gene polymorphisms with Graves' disease. J Clin Immunol 2008;28:298-302.

33. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521-33.

34. Weetman A. The genetics of autoimmune thyroid disease. Horm Metab Res 2009;41:421-5.

35. Glass WG, Sarisky RT, Vecchio AM. Not-so-sweet sixteen: the role of IL-16 in infectious and immune-mediated inflammatory diseases. J Interferon Cytokine Res 2006;26:511-20.

36. Tsai KH, Chang CY, Tsai FJ, Lin HJ, Yang YS, Lim YP, et al. Association of interleukin-16 polymorphisms with graves' disease in a taiwanese population. Chin J Physiol 2014;57:69-75.

37. Lew BL, Chung JH, Sim WY. Association between IL16 gene polymorphisms and susceptibility to alopecia areata in the Korean population. Int J Dermatol 2014;53:319-22.

38. Gao LB, Rao L, Wang YY, Liang WB, Li C, Xue H, et al. The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis 2008;30:295-9.

39. Azimzadeh P, Romani S, Mohebbi SR, Kazemian S, Vahedi M, Almasi S, et al. Interleukin-16 (IL-16) gene polymorphisms in Iranian patients with colorectal cancer. JGLD 2011;20:371-6.

40. Gao LB, Liang WB, Xue H, Rao L, Pan XM, Lv ML, et al. Genetic polymorphism of interleukin-16 and risk of nasopharyngeal carcinoma. Clinica Chimica Acta 2009;409:132-5.

41. Hughes L, Ruth K, Rebbeck TR, Giri VN. Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men. Prostate Cancer Prostatic Dis 2013;16:308-14.

42. Romani S, Hosseini SM, Mohebbi SR, Kazemian S, Derakhshani S, Khanyaghma M, et al. Interleukin-16 gene polymorphisms are considerable host genetic factors for patients’ susceptibility to chronic hepatitis B infection. Hepat Res Treat 2014;790753:5.

43. Eed EM, HusseinYM, Ghonaim MM, Khalifa AS, Alzahrani SS, Alhazmi AS, et al. Interleukin16 and Interleukin 28B Genes Polymorphism in HBV Infected Saudi patients. IOSR-JBB 2015;1:49-54.